Rare diseases
Investigational molecules
Locations
Recruiting trials first
3 clinical trials in this condition
Study on Acoramidis for Preventing Transthyretin Amyloidosis in Young People with a Genetic Risk
BelgiumStudy on the Impact of Dapagliflozin on Quality of Life and Exercise Capacity in Patients with Transthyretin Cardiac Amyloidosis
ItalyA Study of Acoramidis for Long-Term Safety in Patients with Newly Diagnosed Variant Transthyretin Amyloid Cardiomyopathy
BelgiumIn short
Acquired ATTR amyloidosis, also called wild-type ATTR, is a condition that develops as people age, not through genetic inheritance. Understanding how doctors identify this disease through various tests and examinations can help patients recognize when to seek medical attention and what to expect during the diagnostic process.
Acquired ATTR amyloidosis, also known as wild-type ATTR, occurs for no known genetic reason and most commonly affects the heart and nervous system. This form of the disease typically appears in males over 65 years of age, which suggests that both age and sex may be important risk factors.
If you experience symptoms that might indicate heart problems combined with other unexplained issues, it may be time to consider diagnostic testing for acquired ATTR amyloidosis. Common warning signs include shortness of breath, especially during physical activity, swelling in the ankles and legs, abnormal heart rhythms like palpitations, or feelings of lightheadedness. You might also notice tingling or numbness in your hands or feet, unexplained back pain, or digestive problems such as diarrhea, nausea, or unintended weight loss.
Because acquired ATTR amyloidosis is currently underdiagnosed, medical experts believe that many more people have this condition than are actually identified. Some patients may have been previously diagnosed with other conditions such as hypertensive heart disease or simple age-related heart changes, when in fact they have cardiac amyloidosis. This makes it especially important to seek proper diagnostic testing if you have heart failure symptoms that don't seem to fully match typical patterns, or if you have multiple unexplained symptoms affecting different body systems.
People who develop symptoms similar to heart failure but also experience nerve problems, musculoskeletal issues, or gastrointestinal symptoms should discuss the possibility of amyloidosis testing with their healthcare provider. Early diagnosis can help start treatment sooner and potentially slow the progression of organ damage.
Diagnosing acquired ATTR amyloidosis involves multiple steps and different types of tests. The process begins when doctors suspect the condition based on your symptoms and medical history. Because the disease can affect several organs and systems in your body, the diagnostic workup typically includes various tests to confirm the presence of amyloid deposits and determine how much damage they have caused.
One of the first diagnostic procedures doctors may perform is an abdominal fat pad biopsy. This involves taking a small tissue sample from the fatty tissue in your abdomen to look for amyloid deposits under a microscope. While this is a relatively simple procedure, it may not always detect amyloid proteins, so additional testing might be needed.
In some cases, doctors may need to perform biopsies of the affected organs themselves, such as the heart, to determine the extent of organ involvement. A biopsy is a procedure where a small piece of tissue is removed and examined to help doctors diagnose a medical condition. These samples are then studied using special techniques to identify whether amyloid is present and what type it is.
Once amyloid deposits are confirmed, doctors need to determine exactly what type of amyloidosis you have, because different types require different treatments. This distinction is critical because acquired ATTR amyloidosis must be differentiated from other forms, particularly AL amyloidosis, which is caused by a different abnormal protein called light chain.
Doctors use specialized laboratory tests called immunohistochemistry and mass spectrometry to distinguish between ATTR and AL amyloidosis. Immunohistochemistry uses antibodies to identify specific proteins in tissue samples, while mass spectrometry analyzes the molecular composition of the proteins found in your tissues.
Certain imaging scans can also help identify the type of amyloidosis, especially when it affects the heart. These specialized scans can distinguish ATTR from AL amyloidosis without requiring invasive biopsies in some cases.
Blood tests play an important role in the diagnostic process. For acquired ATTR amyloidosis specifically, genetic testing through a blood sample helps confirm that there is no mutation in the TTR gene. This test distinguishes wild-type (acquired) ATTR from hereditary ATTR, which is caused by inherited genetic mutations. If no genetic mutation is found in the TTR gene, this supports the diagnosis of acquired rather than hereditary ATTR amyloidosis.
Beyond confirming the presence and type of amyloid, doctors need to understand how the deposits have affected your organs, particularly your heart and nervous system. This comprehensive assessment involves multiple types of tests that examine different aspects of organ function.
An echocardiogram, which uses sound waves to create moving pictures of your heart, helps doctors see how well your heart is pumping and whether the heart muscle has thickened or stiffened due to amyloid deposits. An electrocardiogram (ECG or EKG) measures the electrical activity of your heart and can reveal abnormal rhythms or conduction problems that might be caused by amyloid buildup.
More advanced imaging tests include magnetic resonance imaging (MRI) scans and other specialized cardiac scans that provide detailed pictures of your heart structure and function. These imaging studies can show characteristic patterns that suggest cardiac amyloidosis and help assess the severity of heart involvement.
If nerve involvement is suspected, doctors may perform nerve and muscle tests to evaluate peripheral nerve function. These tests measure how well electrical signals travel through your nerves and can identify damage caused by amyloid deposits in the nervous system.
Blood tests are also used to check how well your kidneys and other organs are functioning, as amyloid deposits can affect multiple organ systems. These routine laboratory studies help create a complete picture of how the disease is affecting your body.
Because acquired ATTR amyloidosis can cause problems in multiple organ systems, you may need to see several different specialists during the diagnostic process. Your care team might include cardiologists who specialize in heart disease, neurologists who focus on nerve problems, and other specialists depending on which organs are affected. These doctors work together to coordinate your care and ensure that all aspects of the disease are properly evaluated.
The diagnostic process can feel overwhelming because it involves many different tests and appointments. However, this thorough approach is necessary to accurately identify the condition and determine the best treatment plan. Each test provides important information that helps your doctors understand how the disease is affecting your body and what interventions might be most helpful.
For patients interested in participating in clinical trials testing new treatments for acquired ATTR amyloidosis, additional or more specific diagnostic criteria may apply. Clinical trials are research studies that test whether new treatments are safe and effective, and they typically have strict requirements about who can enroll.
Clinical trial qualification often requires documented proof of the diagnosis through biopsy confirmation of amyloid deposits, along with laboratory testing that specifically identifies the amyloid as ATTR type rather than other forms. Genetic testing is particularly important for trial enrollment because many studies need to distinguish between hereditary and acquired forms of ATTR amyloidosis, as these may respond differently to treatments.
Trials typically require detailed assessment of organ involvement and function at the time of enrollment. This baseline evaluation often includes comprehensive cardiac testing with echocardiography and other imaging studies, blood tests to measure specific biomarkers, and assessments of symptoms and quality of life. These baseline measurements establish a starting point that researchers use to determine whether the experimental treatment is having beneficial effects.
Some clinical trials focus specifically on cardiac involvement, while others may study treatments for nerve-related symptoms or multi-organ disease. The diagnostic requirements for trial enrollment depend on what the study is testing. For example, a trial testing a heart-specific treatment might require detailed cardiac imaging and evidence of heart failure, while a study focused on nerve function might emphasize nerve conduction testing and measures of neuropathy.
Patients considering clinical trial participation should discuss their test results with their healthcare team and the trial coordinators to understand whether they meet the specific diagnostic criteria for studies that might be available to them. Clinical trials can provide access to new treatments before they become widely available, but the enrollment process requires careful documentation of your diagnosis and disease stage through standardized diagnostic procedures.
The outlook for people with acquired ATTR amyloidosis depends on several factors, including which organs are affected and how severe the damage is when treatment begins. In general, ATTR amyloidosis is considered less severe and more treatable than AL amyloidosis, which is caused by a different type of abnormal protein. The development of new disease-modifying medications in recent years has significantly improved the outlook for patients with this condition.
The progression of acquired ATTR amyloidosis varies from person to person. Because this type typically occurs in older adults, particularly males over 65, age-related factors can also influence how the disease develops and responds to treatment. Early diagnosis and prompt initiation of treatment are important factors that can positively influence outcomes. When treatment begins before significant organ damage occurs, patients may have better chances of maintaining their quality of life and organ function.
While specific survival statistics for acquired ATTR amyloidosis alone are not provided in the available medical literature, research suggests that long-term treatment may provide survival benefits. Studies following patients treated with specific medications have tracked outcomes for up to nine years in some cases, suggesting that ongoing treatment may help extend survival. The individual prognosis depends greatly on the extent of cardiac involvement, the presence of heart failure, and how well patients respond to available treatments. Better understanding of cardiac amyloidosis and the availability of newer treatments have improved outcomes compared to previous decades when diagnosis often occurred very late in the disease course.
This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
